PMH21: CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH OLANZAPINE IN PATIENTS WITH BIPOLAR DISORDER AS COMPARED WITH HALOPERIDOL  by Shi, L et al.
Abstracts 459
PMH21
CLINICAL AND HEALTH-RELATED QUALITY OF 
LIFE OUTCOMES ASSOCIATED WITH 
OLANZAPINE IN PATIENTS WITH BIPOLAR 
DISORDER AS COMPARED WITH HALOPERIDOL
Shi L1, Namjoshi M1, Zhang F1, Edgell E2, Tohen M1
1Lilly Research Laboratories, Indianapolis, IN, USA; 2 Lilly 
Research Centre, Windlesham, UK
OBJECTIVE: To compare the clinical and health-related
quality of life outcomes associated with olanzapine and
haloperidol treatment in patients with bipolar disorder.
METHODS: Patients (N  453) with bipolar I disorder
(manic or mixed episode) were randomized to either
olanzapine 5–20 mg/day or haloperidol 3–15 mg/day for
12 weeks. The primary clinical outcome was the symp-
tomatic remission rates, as defined a priori by the propor-
tion of patients having a Y-MRS total score 12 and a
HAMD-21 total score  8, at 6 weeks and 12 weeks. The
humanistic outcomes were measured as changes from
baseline to endpoint (week 6 or week 12) in the scores of
the Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36).
RESULTS: Olanzapine-treated patients had a higher re-
mission rate than haloperidol at six weeks (52% versus
46% p  0.15) and at 12 weeks (52% versus 44%, p 
0.08). At week six, significant changes in five SF-36 do-
mains of general health (p  0.010), physical functioning
(p  .001), role limitations due to physical health prob-
lems (p  .001), social functioning (p  .05), and vitality
(p  .01), were found in favor of olanzapine-treated pa-
tients as compared to haloperidol. At week 12, olanza-
pine treatment maintained the significantly favorable changes
in the same domains with the exception of social functioning.
None of the SF-36 domains was in favor of haloperidol at
week 6 or week 12.
CONCLUSIONS: Compared to haloperidol, olanzapine
treatment was associated with the improvements in the
clinical and health-related quality of life outcomes in pa-
tients with bipolar disorder. STATEMENT OF SIGNIFI-
CANCE: Compared to haloperidol, olanzapine treatment
was associated with the improvements in the clinical and
health-related quality of life outcomes in patients with bi-
polar disorder.
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THE USE OF NEFAZODONE IN THE 
TREATMENT OF POST TRAUMATIC 
STRESS DISORDER
Voris JC1, Voris CT2, Kaltsounis J3
1University of South Carolina, Columbia, SC, USA; 2Dorn 
Veterans Hospital, Columbia, SC, USA; 3Bristol-Meyers Squibb 
Co, New York, NY, USA
OBJECTIVE: Examine the utilization and daily dose of
nefazodone compared to that of three SSRIs (fluoxetine,
paroxetine, and sertraline) in the treatment of PTSD and
depression at the Dorn Veterans Medical Center, a hospi-
tal for military veterans.
METHODS: A total of 1761 patients received an SSRI or
nefazodone during the month of December 1999. Fifty
patients from each drug group were randomly selected.
Information on diagnosis and dose were extracted from
the chart and pharmacy records.
RESULTS: PTSD was the primary diagnosis for each drug
as follows: Fluoxetine 16%, nefazodone 52%, paroxetine
24%, and sertraline 10%. The average daily dose of each
drug for depression vs. PTSD is as follows: Fluoxetine
23.8 mg vs. 31.3 mg; nefazodone 291.7 mg vs. 341.0 mg;
paroxetine 24.2 mg vs. 23.8 mg, and sertraline 74.4 mg
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